Earnings

Eli Lilly’s Omvoh Shows 1-Year Phase 3 Results for Kids with Ulcerative Colitis

Oct 19, 2026 · 04:44 AM ET· updated 1h ago

Eli Lilly and Company (NYSE:LLY) today announced positive late-breaking one-year results from the Phase 3 SHINE-2 study of Omvoh (mirikizumab-mrkz) in pediatric patients ages 6 to 17 with moderately to severely active

Why It Matters

Eli Lilly's medicine for kids with ulcerative colitis showed good results over one year. When a company proves its medicine works well, people tend to trust it more.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

LLY1,244.00

-13.03 (-1.04%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.